United States - English - NLM (National Library of Medicine)

eon labs, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use carisoprodol, aspirin and codeine phosphate tablets, usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: • all children younger than 12 years of age (see warnings) • post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see warnings ). carisoprodol, aspirin and codeine phosphate tablets are also contraindicated in patients with: carisoprodol, aspirin, and codeine phosphate tablets contains codeine. codeine in combination with carisoprodol and aspirin is a schedule iii

United States - English - NLM (National Library of Medicine)

apotheca inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [ see dosage and administration (2) ]. carisoprodol tablets usp are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobam

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. pregnancy category c.  there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamat

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e) - carisoprodol 200 mg - carisoprodol and aspirin is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol and aspirin should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol and aspirin is contraindicated in patients with a history of: - a serious gi complication (i.e., bleeding, perforations, obstruction) due to aspirin use - aspirin induced asthma (a symptom complex which occurs in patients who have asthma, rhinosinusitis, and nasal polyps who develop a severe, potentially fatal bronchospasm shortly after taking aspirin or other nsaids) - hypersensitivity reaction to carbamate such as meprobamate - acute intermittent prophyria the efficacy, safety, and pharmacokinetics of carisoprodol and aspirin in pediatric patients less than 16 years

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses (seewarnings ), reserve carisoprodol, aspirin and codeine phosphate tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia carisoprodol, aspirin and codeine phosphate tablets,usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: - all children

United States - English - NLM (National Library of Medicine)

stat rx usa llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskietal conditions in adults.  carisprodol tablets should only be used for short periods (up to two or three weeks) brcause adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculosketal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of carisoprodol during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increased risk for parti

United States - English - NLM (National Library of Medicine)

altura pharmaceuticals, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reactions to a carbamate such as meprobamate there are no data on the use of carisoprodol tablets during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increase

United States - English - NLM (National Library of Medicine)

orient pharma co., ltd. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets usp is indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitation of use carisoprodol tablets usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2) ]. carisoprodol is contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. risk summary data over many decades of carisoprodol use in pregnancy have not identified a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. data on meprobamate, the primary metabolite of carisoprodol, also do not show a consistent association between maternal use of meprobamate and an increased risk of major birth defects (see data). in a publish

United States - English - NLM (National Library of Medicine)

west-ward pharmaceutical corp - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration [see dosage and administration (2) ]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reactions to a carbamate such as meprobamate there are no data on the use of carisoprodol tablets during human pregnancy. animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival. the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic. retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an increase

United States - English - NLM (National Library of Medicine)

aidarex pharmaceuticals llc - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h) - carisoprodol 350 mg - carisoprodol tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. carisoprodol tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see dosage and administration (2)]. carisoprodol tablets are contraindicated in patients with a history of acute intermittent porphyria or a hypersensitivity reaction to a carbamate such as meprobamate. there are no data on the use of carisoprodol tablets during human pregnancy.  animal studies indicate that carisoprodol crosses the placenta and results in adverse effects on fetal growth and postnatal survival.  the primary metabolite of carisoprodol, meprobamate, is an approved anxiolytic.  retrospective, post-marketing studies do not show a consistent association between maternal use of meprobamate and an incre